News tagged with erlotinib

Scientists reverse Alzheimer's-like memory loss in animal models by blocking EGFR signaling

A team of neuroscientists and chemists from the U.S. and China today publish research suggesting that a class of currently used anti-cancer drugs as well as several previously untested synthetic compounds show effectiveness ...

Alzheimer's disease & dementia Sep 24, 2012 | 4.8 / 5 (4) | 0 |

New analysis helps guide use of erlotinib in advanced non-small cell lung cancer

Patients with advanced non-small cell lung cancer should only receive treatment with the drug erlotinib before receiving standard chemotherapy if their tumor is known to harbor EGFR mutations, researchers report at the 3rd ...

Cancer Apr 18, 2012 | 5 / 5 (1) | 0

Lung cancer patients with pockets of resistance prolong disease control by 'weeding the garden'

The central skill of cancer is its ability to mutate – that's how it became cancerous in the first place. Once it's started down that path, it's not so difficult for a cancer cell to mutate again and again. This means that ...

Cancer Dec 01, 2012 | 5 / 5 (1) | 0

Comparing combination therapies for advanced head and neck cancer shows no improvement

Locally advanced squamous cell carcinoma of the head and neck is a potentially curable disease in nearly every patient at the time of diagnosis, yet despite the most aggressive efforts, up to 30-50 percent ...

Cancer Mar 07, 2013 | 1 / 5 (1) | 0

Pages: 1 2
Next »

Erlotinib

Erlotinib hydrochloride (trade name Tarceva) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is a reversible tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR). It is marketed in the United States by Genentech and OSI Pharmaceuticals and elsewhere by Roche. In lung cancer, it extends life by an average of 3.3 months at a cost of CDN$95,000.